三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
R/RCLL最新PFS数据支持BGB-16673开展与匹妥布替尼的头对头试验
R/RCLL最新PFS数据支持BGB-16673开展与匹妥布替尼的头对头试验
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:312KB
图片尺寸:1811*881
同报告图片
/
4
fCDpobnnm64gfCBCR0ItMTY2NzMgfCDljLnlronluIPmm7/lsLwgfAp8LS0tLS0tfC0tLS0tLS0tLS18LS0tLS0tLS0tLXwKfCBuICAgIHwgNjYgICAgICAgfCAxMTkgICAgICB8Cnwg5Lit5L2NUEZTLCDmnIggKDk1JSBDSSkgfCAyMi44ICgxNS42KSB8IDE0LjAgKDExLjItMTYuNikgfAp8IOS4reS9jemaj+iuv+aXtumXtCwg5pyIIHwgMTUuNiAgICAgIHwgMTkuNCAgICAgIHw=
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
fCDlgqzljJbliYIgICAgICAgfCDml7bpl7QgICAgICAgfAp8LS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfAp8IENESzTmipHliLbliYIgICB8IDIwMjVIMSAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjVIMiAgICAgfAp8IEI3LUg0IEFEQyAgICB8IDIwMjVIMSAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjYgICAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjVIMiAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjVIMiAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjVIMiAgICAgfAp8IEI3LUgzIEFEQyAgICB8IDIwMjVIMiAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjVIMiAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjVIMiAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjVIMiAgICAgfAp8IFBSTVQ1K01BVDJBICB8IDIwMjYgICAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjYgICAgICAgfAoK6LWE5paZ5p2l5rqQ77ya5YWs5Y+45ryU56S65p2Q5paZ77yM5Zu96YeR6K+B5Yi456CU56m25omA
fCDntKLmiZjlhYvmi4kgIHwgIFIvUiBNQ0wgMiB8IDIwMjVIMiB8CnwtLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS18LS0tLS0tLS0tfAp8IEJUSyBDREFDIHwgMUwgRVNDQyAgICAgfCAyMDI1SDEgIHwKfCDmm7/pm7fliKnnj6DljZXmipcgfCAxTCBHQyAzICAgICB8IDIwMjVIMiAgfAp8ICvmm7/pm7fliKnnj6DljZXmipcgfCBIRVJJWk9OLTMwMSAxTCBIRVIyK0dFQSAzIOacn+aVsOaNruivu+WHuiB8IDIwMjVIMiAgfAp8IOWhlOaLieWmpeWNleaKlyB8ICAgICAgICAgICAgIHwgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrlhazlj7jmvJTnpLrmnZDmlpnvvIzlm73ph5Hor4HliLjnoJTnqbbmiYA=
所属报告:
百济神州(6160.HK)-港股公司研究报告:龙头Biopharma高举高打商业化和研发迎收获期-250805(31页).pdf
打包全文图表
相关数据
依沃西为全球首个在三期临床中头对头击败K药的新药,PFS强阳性(HR=0.51)
收藏
行业数据
2026-03-31
原图定位
查看详情
HARMONi-6试验主要终点:依沃西+化疗较对照臂PFS提升4.2个月(HR=0.60)
收藏
行业数据
2026-03-31
原图定位
查看详情
CARTITUDE-4 TME: Patients With Shorter PFS (≤18M) and Patients With More pLOT had a More Suppressive TME
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
收藏
行业数据
2026-03-11
原图定位
查看详情
CARTITUDE-4: PFS and OS in Patients With Standard-Risk Cytogenetics (As-Treated)
fCDnu4TliKsgfCAzMOS4quaciOaXoOi/m+WxleeUn+WtmOeOh++8iFBGUywgJe+8iSB8IDMw5Liq5pyI5oC755Sf5a2Y546H77yIT1MsICXvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCBDQVJUSVRVREUgLSA0IOagh+WHhumjjumZqSB8IDgwLjUgfCA4Ny4zIHwKfCBDQVJUSVRVREUgLSA0IOagh+WHhumjjumZqSArIGdhaW4vYW1wKDFxKSB8IDcxLjcgfCA4Ni4xIHwKCui1hOaWmeadpea6kO+8mlBBUlRJVFVERSAtIDQg56CU56m277yI5qCH5YeG6aOO6Zmp57uG6IOe6YGX5Lyg5a2m5oKj6ICFIEFzIC0gVHJlYXRlZCDliIbmnpDvvInmlbDmja4=
收藏
行业数据
2026-03-11
原图定位
查看详情
Figure 3: PFS (A) and OS (B)
fCDmjIfmoIcgICAgICAgfCAzNuS4quaciOeOhyB8IDk1JSDnva7kv6HljLrpl7QgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18CnwgUEZTICAgICAgICB8IDkzLjglICAgIHwgNjMuMuKAkzk5LjEgICAgfAp8IE9TICAgICAgICAgfCA5My44JSAgICB8IDYzLjLigJM5OS4xICAgIHwKCui1hOaWmeadpea6kO+8muWbvueJh+S4reKAnFJlc3VsdHPigJ3mnb/lnZflj4pGaWd1cmUgM++8iFBGUyAoQSkg5ZKMIE9TIChCKe+8ieWGheWuueOAgg==
收藏
行业数据
2026-03-11
原图定位
查看详情
T-DXd对HER2-lowBC的全人群PFS
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
收藏
行业数据
2025-11-24
原图定位
查看详情
Ivonescimab国内临床,PFS显著优于K药
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
收藏
行业数据
2025-10-24
原图定位
查看详情
izabren展现EGFRmNSCLC二线治疗历史最长PFS(单位:月)
fCDmsrvnlpfmlrnmoYggICAgICAgfCBQRlPvvIjmnIjvvIkgfAp8LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLXwKfCBJWkEgLSBCUkVOICAgICB8IDEyLjUgICAgICB8CnwgU0tCMjY0ICAgICAgICAgfCAxMS41ICAgICAgfAp8IEFCQ1AgICAgICAgICAgIHwgOS43ICAgICAgIHwKfCBBSzExMiArIGNoZW1vICB8IDcuNiAgICAgICB8CnwgU0JDUCAgICAgICAgICAgfCA3LjIgICAgICAgfAp8IEhlcjMgLSBkeGQgICAgIHwgNS44ICAgICAgIHwKfCBEYXRvICAgICAgICAgICB8IDUuNCAgICAgICB8CgrotYTmlpnmnaXmupDvvJrljLvoja/prZTmlrnmlbDmja7lupPvvIzlm73ms7DmtbfpgJror4HliLjnoJTnqbbvvJvms6jvvJpTS0IyNjQg5pWw5o2u5p2l6IeqIDIwMjQgQUFDUjs=
收藏
行业数据
2025-09-16
原图定位
查看详情
BGB-43395的剂量爬坡和优化临床设计以及安全性数据
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
收藏
行业数据
2025-08-08
原图定位
查看详情
Vepdegestrantvs氟维司群在HR+/HER2-BC(全人群)的PFS数据
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
收藏
行业数据
2025-08-08
原图定位
查看详情
BGB-43395安全性数据
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
收藏
行业数据
2025-08-07
原图定位
查看详情
CELESTIAL-301临床:全球唯一旨在证明相比目前固定疗程标准疗法具有PFS
fCDliIblsYLlm6DntKAgfCBB57uEIHwgQue7hCB8CnwtLS0tLS0tLS0tLXwtLS0tLXwtLS0tLXwKfCDlubTpvoQoPDY15bKB5a+55q+U4omlNjXlsoEpIHwgICAgIHwgICAgIHwKfCBJR0hWKOeqgeWPmOWvueavlOacqueqgeWPmCkgfCAgICAgfCAgICAgfAp8IOaYr+WQpuS8tOaciTE3cOe8uuWksS9UUDUz56qB5Y+YIHwgICAgIHwgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuOa8lOekuuadkOaWme+8jOWbvemHkeivgeWIuOeglOeptuaJgA==
收藏
行业数据
2025-08-07
原图定位
查看详情
BTKi及BCL2i经治的后线CLL/SLL临床数据(非头对头对比):BGB-16673初步展现治疗优势
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
收藏
行业数据
2025-08-07
原图定位
查看详情
表11、BGB-16673与非共价BTK或其他BTKPROTAC在治疗R/RCLL/SLL的临床数据对比(非头
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
收藏
行业数据
2025-07-24
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
临床数据展现同类最优潜力,头对头 III 期临床彰显信心。BGB-16673 在既往接受过多线治疗的 R/R CLL 患者中观察到显著缓解,针对共价 BTKi+BCL2i 经治患者、共价 BT Ki+非共价 BTKi+BCL2i 经治患者的 ORR 分别达 90.5%、75%。在针对 R/R CLL 适应症的早期临床探索中,BGB-16673 在患者治疗线数更高、既往 BTKi 和 BCL2i 暴露更充分的患者群体中仍展现出相较新一代非共价BTKi匹妥布替尼更优的PFS缓解(非头对头对比)。目前公司已开启针对既往接受过共价 BTK 抑制剂治疗的 R/R CLL/SLL 患者的全球 III 期研究,头对头匹妥布替尼,预计将于 2025 年下半年完成首例患者入组。目前公司针对 BGB-16673 进行了广泛的临床开发,并计划注册申报多种适应症,有望于 2026 年在全球范围申报 CLL/SLL。
行业数据
原图定位
当前图表所属:
百济神州(6160.HK)-港股公司研究报告:龙头Biopharma高举高打商业化和研发迎收获期-250805(31页).pdf
全球NHL发病人数持续增长,其中DLBCL、FL、CLL/SLL、MZL发病率较高
血液瘤分型复杂,NHL(包括CLL/SLL亚型)为核心市场之一
2025年和2026年关键早期催化剂:实体瘤管线迎来密集概念验证
2025年和2026年关键后期催化剂:血液瘤产品组合迎来加速兑现
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》